trial · primary record
177Lu-DOTA-EB-TATE
Neuroendocrine Tumors
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 6 |
| Primary completion | 2025-12-31 |
| Primary endpoint | To evaluate the safety of 177Lu-DOTA-EB-TATE assessed from the number of patients with treatment-related adverse events. |
| Registry ID | NCT05475210 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:54.278Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05475210
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.